New combo therapy aims to boost survival in early oral cancer
NCT ID NCT07267286
First seen Jan 07, 2026 · Last updated May 01, 2026 · Updated 17 times
Summary
This study tests whether adding the immunotherapy drug tirellizumab and chemotherapy before surgery can improve outcomes for people with early-stage oral squamous cell carcinoma (cT1-2N0M0). About 60 participants will be randomly assigned to receive either the drug combination followed by surgery, or surgery alone. The main goal is to see if the new approach increases the number of patients who remain cancer-free for two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HNSCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun yat-sen memorial hospital
Guangzhou, Guangdong, 510000, China
Conditions
Explore the condition pages connected to this study.